Tocagen and ApolloBio Enter License Agreement to Develop and Commercialize Toca 511 and Toca FC in the Greater China Region

Tocagen eligible to receive up to $127 million in upfront payment, development and commercial milestones, plus additional double-digit tiered sales royalties Upfront and near-term development milestones payments total up to $20 million SAN DIEGO and ... Biopharmaceuticals, Oncology, Licensing Tocagen, ApolloBio, immunotherapy, high grade glioma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news